Haisco Pharmaceutical Group (002653) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 reached ¥1,299 million, up 22.05% year-over-year, while net profit attributable to shareholders fell 23.32% to ¥166 million for the quarter.

• Year-to-date revenue was ¥3,300 million, up 19.95% year-over-year, but net profit dropped 22.66% to ¥295 million.

• R&D expenses surged 43.5% year-over-year to ¥542 million, reflecting increased investment in innovative drug development.

Financial highlights

• Operating cash flow for the first nine months was ¥389 million, up 98.63% year-over-year.

• Basic and diluted EPS for Q3 were ¥0.1487, down 23.31% year-over-year; year-to-date EPS was ¥0.2637, down 22.65%.

• Total assets at quarter-end were ¥7,214 million, up 6.11% from year-end 2024.

• Owner's equity attributable to shareholders was ¥4,227 million, up 0.33% from year-end.

• Non-recurring losses included a ¥21 million loss from other operating income and expenses.

Outlook and guidance

• Increased R&D investment aims to enhance long-term competitiveness, with a focus on innovative drug pipelines.